公开(公告)号：US20190110687A1

公开(公告)日：2019-04-18

申请号：US16085210

申请日：2017-03-16

Applicant: OHIO STATE INNOVATION FOUNDATION

Inventor： James COE ,  Heather ALLEN ,  Charles HITCHCOCK ,  Edward W. MARTIN

IPC: A61B5/00 ,  G01J3/42

Abstract: Disclosed are systems and methods utilizing an infrared probe and discriminating software to rapidly discriminate normal tissue processes from normal tissue during surgery, physical examination of in-situ lesions, and in the assessment of biopsy and resected tissue specimens. Examples demonstrate discrimination of cancerous from noncancerous tissues. The discriminating software, i.e. the metrics, algorithms, calibrant spectra, and decision equations, allows tissue to be identified as abnormal or normal using a minimum of infrared (IR) wavelengths in order to be measured rapidly. The probe records IR metrics approximately 1000 times faster than current commercial instruments, i.e. on a timescale fast enough for clinical use. The probe uses a tunable mid-infrared laser with a small set of selected wavelengths that are optimized for detecting the chemical and molecular signatures of tissue specific lesions to include, but not limited to, cancer, preneoplasia, intracellular accumulations (e.g. steatosis), inflammation, and wound healing.

公开(公告)号：US20250017470A1

公开(公告)日：2025-01-16

申请号：US18639245

申请日：2024-04-18

Applicant: OHIO STATE INNOVATION FOUNDATION

Inventor： James COE ,  Heather ALLEN ,  Charles HITCHCOCK ,  Edward W. MARTIN

IPC: A61B5/00 ,  A61B17/00 ,  A61B90/00 ,  G01J3/42 ,  G01N21/3563 ,  G01N21/552

Abstract: Disclosed are systems and methods utilizing an infrared probe and discriminating software to rapidly discriminate abnormal tissue processes from normal tissue during surgery, physical examination of in-situ lesions, and in the assessment of biopsy and resected tissue specimens. Examples demonstrate discrimination of cancerous from noncancerous tissues. The discriminating software, i.e. the metrics, algorithms, calibrant spectra, and decision equations, allows tissue to be identified as abnormal or normal using a minimum of infrared (IR) wavelengths in order to be measured rapidly. The probe records IR metrics approximately 1000 times faster than current commercial instruments, i.e. on a timescale fast enough for clinical use. The probe uses a tunable mid-infrared laser with a small set of selected wavelengths that are optimized for detecting the chemical and molecular signatures of tissue specific lesions to include, but not limited to, cancer, preneoplasia, intracellular accumulations (e.g. steatosis), inflammation, and wound healing.

公开(公告)号：US20230346223A1

公开(公告)日：2023-11-02

申请号：US18139722

申请日：2023-04-26

Applicant: OHIO STATE INNOVATION FOUNDATION

Inventor： James COE ,  Heather ALLEN ,  Charles HITCHCOCK ,  Edward W. MARTIN

IPC: A61B5/00 ,  G01N21/552 ,  G01N21/3563 ,  G01J3/42

CPC classification number: A61B5/0075 ,  G01N21/552 ,  G01N21/3563 ,  A61B5/444 ,  G01J3/42 ,  A61B2090/373

Abstract: Disclosed are systems and methods utilizing an infrared probe and discriminating software to rapidly discriminate abnormal tissue processes from normal tissue during surgery, physical examination of in-situ lesions, and in the assessment of biopsy and resected tissue specimens. Examples demonstrate discrimination of cancerous from noncancerous tissues. The discriminating software, i.e. the metrics, algorithms, calibrant spectra, and decision equations, allows tissue to be identified as abnormal or normal using a minimum of infrared (IR) wavelengths in order to be measured rapidly. The probe records IR metrics approximately 1000 times faster than current commercial instruments, i.e. on a timescale fast enough for clinical use. The probe uses a tunable mid-infrared laser with a small set of selected wavelengths that are optimized for detecting the chemical and molecular signatures of tissue specific lesions to include, but not limited to, cancer, preneoplasia, intracellular accumulations (e.g. steatosis), inflammation, and wound healing.